[HTML][HTML] The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
[HTML][HTML] History and progress of hypotheses and clinical trials for Alzheimer's disease
PP Liu, Y Xie, XY Meng, JS Kang - Signal transduction and targeted …, 2019 - nature.com
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …
TREM2—a key player in microglial biology and Alzheimer disease
Alzheimer disease (AD) is a debilitating dementia believed to result from the deposition of
extracellular amyloid-β (Aβ)-containing plaques followed by the formation of neurofibrillary …
extracellular amyloid-β (Aβ)-containing plaques followed by the formation of neurofibrillary …
The complexity of Alzheimer's disease: an evolving puzzle
The history of Alzheimer's disease (AD) started in 1907, but we needed to wait until the end
of the century to identify the components of pathological hallmarks and genetic subtypes and …
of the century to identify the components of pathological hallmarks and genetic subtypes and …
The amyloid cascade hypothesis: an updated critical review
Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …
disease have created excitement and have been heralded as corroboration of the amyloid …
[HTML][HTML] The genetic landscape of Alzheimer disease: clinical implications and perspectives
C Van Cauwenberghe, C Van Broeckhoven… - Genetics in …, 2016 - nature.com
The search for the genetic factors contributing to Alzheimer disease (AD) has evolved
tremendously throughout the years. It started from the discovery of fully penetrant mutations …
tremendously throughout the years. It started from the discovery of fully penetrant mutations …
[HTML][HTML] Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies
Abnormal deposition of misprocessed and aggregated proteins is a common final pathway
of most neurodegenerative diseases, including Alzheimer's disease (AD). AD is …
of most neurodegenerative diseases, including Alzheimer's disease (AD). AD is …
[HTML][HTML] Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer's disease phenotypes
The dismal success rate of clinical trials for Alzheimer's disease (AD) motivates us to
develop model systems of AD pathology that have higher predictive validity. The advent of …
develop model systems of AD pathology that have higher predictive validity. The advent of …
[HTML][HTML] Interactions of pathological proteins in neurodegenerative diseases
Neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal lobar
degeneration (FTD), Lewy body disease (LBD), Parkinson's disease (PD), and amyotrophic …
degeneration (FTD), Lewy body disease (LBD), Parkinson's disease (PD), and amyotrophic …
[PDF][PDF] Biomarker modeling of Alzheimer's disease
CR Jack, DM Holtzman - Neuron, 2013 - cell.com
Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological
abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many …
abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many …